190 related articles for article (PubMed ID: 36753744)
41. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
42. FTO promotes cervical cancer cell proliferation, colony formation, migration and invasion via the regulation of the BMP4/Hippo/YAP1/TAZ pathway.
Huang J; Yang J; Zhang Y; Lu D; Dai Y
Exp Cell Res; 2023 Jun; 427(1):113585. PubMed ID: 37030332
[TBL] [Abstract][Full Text] [Related]
43. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
44. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
45. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
46. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.
Chen CH; Chang AY; Li SH; Tsai HT; Shiu LY; Su LJ; Wang WL; Chiu TJ; Luo SD; Huang TL; Chien CY
Mol Cancer; 2015 Apr; 14():83. PubMed ID: 25889801
[TBL] [Abstract][Full Text] [Related]
47. Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.
Lv C; Hong Y; Miao L; Li C; Xu G; Wei S; Wang B; Huang C; Jiao B
Cell Death Dis; 2013 Dec; 4(12):e952. PubMed ID: 24309939
[TBL] [Abstract][Full Text] [Related]
48. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.
Xu MZ; Chan SW; Liu AM; Wong KF; Fan ST; Chen J; Poon RT; Zender L; Lowe SW; Hong W; Luk JM
Oncogene; 2011 Mar; 30(10):1229-40. PubMed ID: 21076472
[TBL] [Abstract][Full Text] [Related]
49. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
Ito T; Nakamura A; Tanaka I; Tsuboi Y; Morikawa T; Nakajima J; Takai D; Fukayama M; Sekido Y; Niki T; Matsubara D; Murakami Y
Cancer Sci; 2019 Jul; 110(7):2284-2295. PubMed ID: 31069869
[TBL] [Abstract][Full Text] [Related]
50. Function of AXL and molecular mechanisms in regulation of nasopharyngeal carcinoma.
Zhou K; Zhao J; Xu H; Yan X; Liu W; Jiang X; Ren C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):685-697. PubMed ID: 35837768
[TBL] [Abstract][Full Text] [Related]
51. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
52. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
53. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
[TBL] [Abstract][Full Text] [Related]
54. YAP1/Piezo1 involve in the dynamic changes of lymphatic vessels in UVR-induced photoaging progress to squamous cell carcinoma.
Yang YL; Zhou C; Chen Q; Shen SZ; Li JD; Wang XL; Wang PR
J Transl Med; 2023 Nov; 21(1):820. PubMed ID: 37974224
[TBL] [Abstract][Full Text] [Related]
55. GNAS
Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
[TBL] [Abstract][Full Text] [Related]
56. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.
Martin D; Degese MS; Vitale-Cross L; Iglesias-Bartolome R; Valera JLC; Wang Z; Feng X; Yeerna H; Vadmal V; Moroishi T; Thorne RF; Zaida M; Siegele B; Cheong SC; Molinolo AA; Samuels Y; Tamayo P; Guan KL; Lippman SM; Lyons JG; Gutkind JS
Nat Commun; 2018 Jul; 9(1):2372. PubMed ID: 29985391
[TBL] [Abstract][Full Text] [Related]
57. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
58. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis.
Mo Y; Leung LL; Mak CSL; Wang X; Chan WS; Hui LMN; Tang HWM; Siu MKY; Sharma R; Xu D; Tsui SKW; Ngan HYS; Yung MMH; Chan KKL; Chan DW
Mol Cancer; 2023 Jan; 22(1):4. PubMed ID: 36624516
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin.
Liu C; Feng X; Wang B; Wang X; Wang C; Yu M; Cao G; Wang H
Cancer Sci; 2018 Mar; 109(3):688-698. PubMed ID: 29284199
[TBL] [Abstract][Full Text] [Related]
60. HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature.
Mathiot L; Herbreteau G; Robin S; Fenat C; Bennouna J; Blanquart C; Denis M; Pons-Tostivint E
Curr Oncol; 2022 May; 29(5):3748-3758. PubMed ID: 35621690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
